These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 30378443)

  • 1. Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator.
    Billoir P; Barbay V; Joly LM; Fresel M; Chrétien MH; Le Cam Duchez V
    Ann Pharmacother; 2019 Apr; 53(4):341-347. PubMed ID: 30378443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.
    von Horn H; Rasmusson A; Söderblom L; Malmström RE; Antovic J
    Int J Lab Hematol; 2022 Feb; 44(1):163-167. PubMed ID: 34523813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective cohort study on the use of low molecular weight heparin calibrated anti-Xa assay for measurement of direct oral Xa inhibitors in ex vivo patient samples.
    Lim MS; Hayes R; Sharma A; Kitiponchai T; Mohamed M; Mcrae S
    Pathology; 2022 Aug; 54(5):599-605. PubMed ID: 35414442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations.
    Margetić S; Ćelap I; Delić Brkljačić D; Pavlović N; Šupraha Goreta S; Kobasić I; Lovrenčić-Huzjan A; Bašić Kes V
    Biochem Med (Zagreb); 2020 Feb; 30(1):010702. PubMed ID: 31839722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of global laboratory methods and establishing on-therapy ranges for monitoring apixaban and rivaroxaban: Experience at a single institution.
    Park SH; Seo YH; Park PW; Kim KH; Seo JY; Lee HT; Kwoun WJ; Ahn JY
    J Clin Lab Anal; 2019 Jun; 33(5):e22869. PubMed ID: 30860622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin Anti-Xa Activity, a Readily Available Unique Test to Quantify Apixaban, Rivaroxaban, Fondaparinux, and Danaparoid Levels.
    Boissier E; Senage T; Babuty A; Gouin-Thibault I; Rozec B; Roussel JC; Sigaud M; Ternisien C; Trossaert M; Fouassier M; Lakhal K
    Anesth Analg; 2021 Mar; 132(3):707-716. PubMed ID: 32833716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heparin-Calibrated Anti-Factor Xa Assay for the Measurement of Direct Anticoagulants such as Apixaban, Rivaroxaban, and Edoxaban.
    Ahn HS; Chae H; Kim Y; Lee HK; Kim H
    Clin Lab; 2024 Sep; 70(9):. PubMed ID: 39257123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors.
    Beyer J; Trujillo T; Fisher S; Ko A; Lind SE; Kiser TH
    Clin Appl Thromb Hemost; 2016 Jul; 22(5):423-8. PubMed ID: 26842561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
    Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles.
    Goto E; Horinaka S; Ishimitsu T; Kato T
    Drug Metab Pharmacokinet; 2020 Feb; 35(1):151-159. PubMed ID: 32007354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multianalyte Determination of NOACs Using LC-MS/MS and Comparison with Functional Coagulation Assays.
    Slavik L; Lukes J; Friedecky D; Zhanelova M; Nemcova M; Ulehlova J; Prochazkova J; Hlusi A; Palova M; Vaclavik J
    Clin Lab; 2018 Oct; 64(10):1611-1621. PubMed ID: 30336535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin-Calibrated Chromogenic Anti-Xa Activity Measurements in Patients Receiving Rivaroxaban: Can This Test Be Used to Quantify Drug Level?
    Gosselin RC; Francart SJ; Hawes EM; Moll S; Dager WE; Adcock DM
    Ann Pharmacother; 2015 Jul; 49(7):777-83. PubMed ID: 25855705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Anti-Xa Activity in Patients Receiving Apixaban or Rivaroxaban.
    Bookstaver DA; Sparks K; Pybus BS; Davis DK; Marcsisin SR; Sousa JC
    Ann Pharmacother; 2018 Mar; 52(3):251-256. PubMed ID: 29047306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.
    Testa S; Legnani C; Tripodi A; Paoletti O; Pengo V; Abbate R; Bassi L; Carraro P; Cini M; Paniccia R; Poli D; Palareti G
    J Thromb Haemost; 2016 Nov; 14(11):2194-2201. PubMed ID: 27566988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of apixaban anti-factor Xa assay and impact of body weight.
    Wasan SM; Feland N; Grant R; Aston CE
    Thromb Res; 2019 Oct; 182():51-55. PubMed ID: 31450008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
    Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
    J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Commercial Low Molecular Weight Heparin and Homemade Anti-Xa Calibrators to a Commercial Specific Anti-Xa Calibrator for Plasma Rivaroxaban Quantification by Anti-Xa Oral Anticoagulant Plasma Concentration Chromogenic Assay.
    Divsalar B; Kalantari T; Mohebbi S; Bahmanimehr A; Shahsavani A; Borhani-Haghighi A
    Lab Med; 2023 Jul; 54(4):400-405. PubMed ID: 36573788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measuring Direct Oral Anticoagulants.
    Gosselin RC; Douxfils J
    Methods Mol Biol; 2017; 1646():217-225. PubMed ID: 28804832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of low plasma concentrations of apixaban in the periprocedural setting.
    Lessire S; Dincq AS; Siriez R; Pochet L; Sennesael AL; Vornicu O; Hardy M; Deceuninck O; Douxfils J; Mullier F
    Int J Lab Hematol; 2020 Aug; 42(4):394-402. PubMed ID: 32297711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.